Gut microbiota, short chain fatty acids, and obesity across the epidemiologic transition: the METS-Microbiome study protocol

Simple item page
dc.contributor.authorDugas, Lara R
dc.contributor.authorLie, Louise
dc.contributor.authorPlange-Rhule, Jacob
dc.contributor.authorBedu-Addo, Kweku
dc.contributor.authorBovet, Pascal
dc.contributor.authorLambert, Estelle V
dc.contributor.authorForrester, Terrence E
dc.contributor.authorLuke, Amy
dc.contributor.authorGilbert, Jack A
dc.contributor.authorLayden, Brian T
dc.date.accessioned2018-08-28T11:49:45Z
dc.date.available2018-08-28T11:49:45Z
dc.date.issued2018-08-06
dc.date.updated2018-08-12T03:34:25Z
dc.description.abstractBackground While some of the variance observed in adiposity and weight change within populations can be accounted for by traditional risk factors, a new factor, the gut microbiota, has recently been associated with obesity. However, the causal mechanisms through which the gut microbiota and its metabolites, short chain fatty acids (SCFAs) influence obesity are unknown, as are the individual obesogenic effects of the individual SCFAs (butyrate, acetate and propionate). This study, METS-Microbiome, proposes to examine the influence of novel risk factors, the gut microbiota and SCFAs, on obesity, adiposity and weight change in an international established cohort spanning the epidemiologic transition. Methods The parent study; Modeling the Epidemiologic Transition Study (METS) is a well-established and ongoing prospective cohort study designed to assess the association between body composition, physical activity, and relative weight, weight gain and cardiometabolic disease risk in five diverse population-based samples in 2500 people of African descent. The cohort has been prospectively followed since 2009. Annual measures of obesity risk factors, including body composition, objectively measured physical activity and dietary intake, components which vary across the spectrum of social and economic development. In our new study; METS-Microbiome, in addition to continuing yearly measures of obesity risk, we will also measure gut microbiota and stool SCFAs in all contactable participants, and follow participants for a further 3 years, thus providing one of the largest gut microbiota population-based studies to date. Discussion This new study capitalizes upon an existing, extensively well described cohort of adults of African-origin, with significant variability as a result of the widespread geographic distributions, and therefore variation in the environmental covariate exposures. The METS-Microbiome study will substantially advance the understanding of the role gut microbiota and SCFAs play in the development of obesity and provide novel obesity therapeutic targets targeting SCFAs producing features of the gut microbiota. Trial registration Registered NCT03378765 Date first posted: December 20, 2017.
dc.identifier.apacitationDugas, L. R., Lie, L., Plange-Rhule, J., Bedu-Addo, K., Bovet, P., Lambert, E. V., ... Layden, B. T. (2018). Gut microbiota, short chain fatty acids, and obesity across the epidemiologic transition: the METS-Microbiome study protocol. <i>BMC Public Health</i>, http://hdl.handle.net/11427/28342en_ZA
dc.identifier.chicagocitationDugas, Lara R, Louise Lie, Jacob Plange-Rhule, Kweku Bedu-Addo, Pascal Bovet, Estelle V Lambert, Terrence E Forrester, Amy Luke, Jack A Gilbert, and Brian T Layden "Gut microbiota, short chain fatty acids, and obesity across the epidemiologic transition: the METS-Microbiome study protocol." <i>BMC Public Health</i> (2018) http://hdl.handle.net/11427/28342en_ZA
dc.identifier.citationBMC Public Health. 2018 Aug 06;18(1):978
dc.identifier.ris TY - Journal Article AU - Dugas, Lara R AU - Lie, Louise AU - Plange-Rhule, Jacob AU - Bedu-Addo, Kweku AU - Bovet, Pascal AU - Lambert, Estelle V AU - Forrester, Terrence E AU - Luke, Amy AU - Gilbert, Jack A AU - Layden, Brian T AB - Background While some of the variance observed in adiposity and weight change within populations can be accounted for by traditional risk factors, a new factor, the gut microbiota, has recently been associated with obesity. However, the causal mechanisms through which the gut microbiota and its metabolites, short chain fatty acids (SCFAs) influence obesity are unknown, as are the individual obesogenic effects of the individual SCFAs (butyrate, acetate and propionate). This study, METS-Microbiome, proposes to examine the influence of novel risk factors, the gut microbiota and SCFAs, on obesity, adiposity and weight change in an international established cohort spanning the epidemiologic transition. Methods The parent study; Modeling the Epidemiologic Transition Study (METS) is a well-established and ongoing prospective cohort study designed to assess the association between body composition, physical activity, and relative weight, weight gain and cardiometabolic disease risk in five diverse population-based samples in 2500 people of African descent. The cohort has been prospectively followed since 2009. Annual measures of obesity risk factors, including body composition, objectively measured physical activity and dietary intake, components which vary across the spectrum of social and economic development. In our new study; METS-Microbiome, in addition to continuing yearly measures of obesity risk, we will also measure gut microbiota and stool SCFAs in all contactable participants, and follow participants for a further 3 years, thus providing one of the largest gut microbiota population-based studies to date. Discussion This new study capitalizes upon an existing, extensively well described cohort of adults of African-origin, with significant variability as a result of the widespread geographic distributions, and therefore variation in the environmental covariate exposures. The METS-Microbiome study will substantially advance the understanding of the role gut microbiota and SCFAs play in the development of obesity and provide novel obesity therapeutic targets targeting SCFAs producing features of the gut microbiota. Trial registration Registered NCT03378765 Date first posted: December 20, 2017. DA - 2018-08-06 DB - OpenUCT DP - University of Cape Town J1 - BMC Public Health LK - https://open.uct.ac.za PB - University of Cape Town PY - 2018 T1 - Gut microbiota, short chain fatty acids, and obesity across the epidemiologic transition: the METS-Microbiome study protocol TI - Gut microbiota, short chain fatty acids, and obesity across the epidemiologic transition: the METS-Microbiome study protocol UR - http://hdl.handle.net/11427/28342 ER - en_ZA
dc.identifier.urihttps://doi.org/10.1186/s12889-018-5879-6
dc.identifier.urihttp://hdl.handle.net/11427/28342
dc.identifier.vancouvercitationDugas LR, Lie L, Plange-Rhule J, Bedu-Addo K, Bovet P, Lambert EV, et al. Gut microbiota, short chain fatty acids, and obesity across the epidemiologic transition: the METS-Microbiome study protocol. BMC Public Health. 2018; http://hdl.handle.net/11427/28342.en_ZA
dc.language.isoen
dc.publisherBioMed Central
dc.publisher.departmentMRC/UCT RU for Exercise and Sport Medicineen_ZA
dc.publisher.facultyFaculty of Health Sciencesen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.rights.holderThe Author(s).
dc.sourceBMC Public Health
dc.source.urihttps://bmcpublichealth.biomedcentral.com/
dc.subject.otherEpidemiologic transition
dc.subject.otherGut microbiota
dc.subject.otherShort chain fatty acids
dc.subject.otherObesity
dc.titleGut microbiota, short chain fatty acids, and obesity across the epidemiologic transition: the METS-Microbiome study protocol
dc.typeJournal Article
uct.type.filetypeText
uct.type.filetypeImage
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Dugas_2018_Article.pdf
Size:
625.62 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.72 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles